Literature DB >> 1816011

[Flow cytometric analysis of cellular DNA content in Barret's esophagus. A study of 66 cases].

M Robaszkiewicz1, E Hardy, A Volant, J B Nousbaum, J M Cauvin, G Calament, F X Robert, J P Saleun, H Gouerou.   

Abstract

Dysplasia is the only marker for malignant potential in Barrett's esophagus. The histologic interpretation of dysplasia is sometimes difficult, particularly when attempting to distinguish dysplastic changes from those of a regenerating and inflammatory mucosa. In order to find an objective marker to identify patients with high risk of malignant transformation, the authors evaluated 497 biopsies from 66 patients with Barrett's esophagus with flow cytometry. The aim of the study was to correlate DNA content and proliferative abnormalities with histology. All biopsies classified histologically as negative for dysplasia had a diploid DNA content. The percentage of biopsies with an aneuploid DNA content increased with the histologic grade of dysplasia: 2 percent of indefinite dysplasia, 11 percent of low grade dysplasia, 44 percent of high grade dysplasia and 78 percent of biopsy specimens with cancer biopsies were aneuploid. Mean S and G2M fractions of diploid biopsy specimens increased with the severity of histologic changes. The S and G2M fraction threshold values that could differentiate patients that were negative for dysplasia from those with high grade dysplasia or cancer were 9 percent and 6 percent, respectively. Aneuploidy or G2M fraction greater than 6 percent was the best discriminating criteria between those two distinct groups of patients. All 6 patients with high grade dysplasia or cancer had aneuploid cell populations or increased G2M fraction, whereas none of the 35 patients whose biopsies were histologically negative for dysplasia had evidence of genomic instability or increased G2M fraction. Flow cytometric abnormalities were found in 10 out of 25 patients whose biopsies were classified as indefinite for dysplasia or low grade dysplasia.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1816011

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  6 in total

Review 1.  Early events during neoplastic progression in Barrett's esophagus.

Authors:  Brian J Reid
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

Review 2.  Genetic Insights in Barrett's Esophagus and Esophageal Adenocarcinoma.

Authors:  Brian J Reid; Thomas G Paulson; Xiaohong Li
Journal:  Gastroenterology       Date:  2015-07-21       Impact factor: 22.682

3.  Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables.

Authors:  P S Rabinovitch; G Longton; P L Blount; D S Levine; B J Reid
Journal:  Am J Gastroenterol       Date:  2001-11       Impact factor: 10.864

4.  Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets.

Authors:  B J Reid; D S Levine; G Longton; P L Blount; P S Rabinovitch
Journal:  Am J Gastroenterol       Date:  2000-07       Impact factor: 10.864

Review 5.  Molecular markers and staging of early esophageal cancer.

Authors:  Stefan B Hosch; Nikolas H Stoecklein; Jakob R Izbicki
Journal:  Langenbecks Arch Surg       Date:  2003-02-20       Impact factor: 3.445

6.  Comparison of DNA histograms by standard flow cytometry and image cytometry on sections in Barrett's adenocarcinoma.

Authors:  Qin Huang; Chenggong Yu; Xiaoqi Zhang; Raj K Goyal
Journal:  BMC Clin Pathol       Date:  2008-05-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.